225.27

0.22% -0.67

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Why ALNY Down? Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $225.27, with a volume of 217.95K. It is down -0.22% in the last 24 hours and down -16.22% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Previous Close:

$224.60

Open:

$226.27

24h Volume:

217.95K

Relative Volume:

0.14

Market Cap:

$30.15B

Revenue:

$4.29B

Net Income/Loss:

$577.22M

P/E Ratio:

53.53

EPS:

4.2086

Net Cash Flow:

$641.34M

1W Performance:

+1.31%

1M Performance:

-16.22%

6M Performance:

-32.64%

1Y Performance:

-50.95%

1-Day Range:

$222.01

$226.27

1-Week Range:

$219.00

$228.98

52-Week Range:

$197.81

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1084)

Industry

Biotechnology (606)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,500

Twitter

@alnylam

Next Earnings Date

2026-07-30

Latest SEC Filings

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALNY Alnylam Pharmaceuticals Inc	225.32	30.60B	4.29B	577.22M	641.34M	4.2086
VRTX Vertex Pharmaceuticals Inc	525.02	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	813.60	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	994.03	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.59	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	365.31	39.31B	5.76B	514.49M	1.10B	4.4813

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Downgrade	Jefferies	Buy → Hold
Jan-28-26	Resumed	Barclays	Overweight
Jan-07-26	Resumed	Oppenheimer	Outperform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Mar-31-25	Initiated	Redburn Atlantic	Buy
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

Aug 17, 2026

Familial Amyloid Polyneuropathy Market - Future Market Insights

Aug 17, 2026

ALNY Looks 56.7% Undervalued on GF Value™ - GuruFocus

Aug 17, 2026

Alnylam Pharmaceuticals (ALNY): Investor Outlook With A 62.82% Potential Upside - DirectorsTalk Interviews

Aug 17, 2026

Aug 16, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out - ACCESS Newswire

Aug 16, 2026

Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - PR Newswire

Aug 16, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Aug 16, 2026

S&CO Inc. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Aug 16, 2026

SCS Capital Management LLC Invests $34.78 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Aug 16, 2026

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing - The Motley Fool

Aug 16, 2026

Aug 15, 2026

Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo - Moomoo

Aug 15, 2026

Kessler Topaz Meltzer & Check, LLP Encourages Alnylam - GlobeNewswire

Aug 15, 2026

Aug 14, 2026

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - The AI Journal

Aug 14, 2026

ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256 - GuruFocus

Aug 14, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company - MarketBeat

Aug 14, 2026

S&P 500 Futures Climb In Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead - Moomoo

Aug 14, 2026

Aug 13, 2026

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test - simplywall.st

Aug 13, 2026

Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318 - Moomoo

Aug 13, 2026

Securities Fraud Investigation Into Alnylam - GlobeNewswire

Aug 13, 2026

Aug 12, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV

Aug 12, 2026

Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)? - simplywall.st

Aug 12, 2026

Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Aug 12, 2026

Aug 11, 2026

Drugs that missed the mark in pharma’s last earnings round - Pharma Voice

Aug 11, 2026

Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Aug 2026 $ALNY - marketbeat.com

Aug 11, 2026

Aug 10, 2026

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - benzinga.com

Aug 10, 2026